Oxford BioMedica reports positive results for advanced colorectal cancer drug

Oxford BioMedica reports positive results for advanced colorectal cancer drug

February 24, 2017 Off By Dino Mustafić

Oxford BioMedicahas said that results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC) were positive with good responses of anti-5T4.

The company said that the study findings demonstrated that significant anti-5T4 immune responses were generated at treatment day 43. Secondary analysis revealed that both CPM and TroVax independently induced highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity. This was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.

Commenting on the results, John Dawson, Chief Executive Officer of Oxford BioMedica, said: “The presentation by the Clinical Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC Clinical Immuno-Oncology symposium showed the potential benefit that Oxford BioMedica’s immunotherapy (TroVax) treatment could give to patients with advanced colorectal cancer.”